Immune Checkpoint Inhibitor-induced Polymyalgia Rheumatica
DFL Liew, SL Mackie, A Tison… - Rheumatic …, 2024 - rheumatic.theclinics.com
Polymyalgia rheumatica (PMR) immune-related adverse events (ICI-PMR) are a subtype of
rheumatic immune-related adverse event (irAE) arising following immune checkpoint …
rheumatic immune-related adverse event (irAE) arising following immune checkpoint …
Diagnosing vasculitis with ultrasound: findings and pitfalls
WA Schmidt, VS Schäfer - Therapeutic Advances in …, 2024 - journals.sagepub.com
Rheumatologists are increasingly utilizing ultrasound for suspected giant cell arteritis (GCA)
or Takayasu arteritis (TAK). This enables direct confirmation of a suspected diagnosis within …
or Takayasu arteritis (TAK). This enables direct confirmation of a suspected diagnosis within …
[HTML][HTML] Recommendations of the French Society of Rheumatology for the management in current practice of patients with polymyalgia rheumatica
D Wendling, O Al Tabaa, B Chevet, O Fakih… - Joint Bone Spine, 2024 - Elsevier
Objective To develop recommendations for the routine management of patients with
polymyalgia rheumatica (PMR). Methods Following standard procedures, a systematic …
polymyalgia rheumatica (PMR). Methods Following standard procedures, a systematic …
Investigational agents for polymyalgia rheumatica treatment: assessing the critical needs for future development
Introduction Polymyalgia rheumatica (PMR) is an inflammatory rheumatic disorder
characterized by pain and stiffness in the shoulder and pelvic girdles, constitutional …
characterized by pain and stiffness in the shoulder and pelvic girdles, constitutional …
The DANIsh VASculitis cohort study: protocol for a national multicenter prospective study including incident and prevalent patients with giant cell arteritis and …
BD Nielsen, S Kristensen, A Donskov, L Terslev… - Frontiers in …, 2024 - frontiersin.org
The DANIsh VASculitis cohort study, DANIVAS, is an observational national multicenter
study with the overall aim to prospectively collect protocolized clinical data and biobank …
study with the overall aim to prospectively collect protocolized clinical data and biobank …
Referral of patients with suspected polymyalgia rheumatica: how complete is our view of 'planet PMR?'
D Camellino, EL Matteson - Annals of the Rheumatic Diseases, 2024 - ard.bmj.com
Polymyalgia rheumatica (PMR) is the second most common inflammatory rheumatic disease
after rheumatoid arthritis in persons older than 50 years, 1 reaching an estimated …
after rheumatoid arthritis in persons older than 50 years, 1 reaching an estimated …
The emerging risk of overdiagnosis in rheumatoid arthritis and polymyalgia rheumatica
E Nettleton, K Carlson, M Putman - The Lancet Rheumatology, 2024 - thelancet.com
Overdiagnosis occurs when patients are diagnosed with a disease that would otherwise
never have affected the quality or duration of their lives. This often happens unintentionally …
never have affected the quality or duration of their lives. This often happens unintentionally …
A History of Polymyalgia Rheumatica: A Narrative Review
S Shah, S Rao, SL Mackie, CB Mukhtyar - Rheumatology, 2024 - academic.oup.com
Polymyalgia rheumatica (PMR) is characterised by stiffness and pain in the shoulders, hips,
and neck and presents most commonly in the eighth decade. It can coexist with giant cell …
and neck and presents most commonly in the eighth decade. It can coexist with giant cell …
Low incidence of late-onset giant cell arteritis during the first year in patients with polymyalgia rheumatica–a repeated imaging study
AW Nielsen, EM Hauge, IT Hansen, BD Nielsen… - …, 2024 - academic.oup.com
Objective The objective was to investigate the incidence of late-onset giant cell arteritis
(GCA) within the first year in patients diagnosed with polymyalgia rheumatica (PMR) …
(GCA) within the first year in patients diagnosed with polymyalgia rheumatica (PMR) …
Real-world outcomes of a dedicated fast-track polymyalgia rheumatica clinic
Objectives To examine the clinical impact of a fast-track PMR clinic to enable early diagnosis
and treatment, and to define both patient and disease characteristics in newly diagnosed …
and treatment, and to define both patient and disease characteristics in newly diagnosed …